Biopharma Sentiment Index | Q3 2026 survey results
The latest BPSI shows dramatic improvements in biopharma conditions and a level of optimism not seen in years. It's official: Biopharma is finally in a good mood. For the first time since the four-year downturn ...
The latest BPSI (Biopharma Sentiment Index) survey shows remarkable improvements in the biopharma industry, marking a significant shift towards positive sentiment. For the first time since the pandemic's four-year downturn, biopharma is now experiencing optimism. The Endpoints News BPSI headline score reached 105 in Q3, an increase from 96 in the previous quarter. Anything above 100 is considered upbeat. The industry has been on a rapid and steady climb since last year, with a nearly 29-point increase in Q3.
This surge in sentiment is evident across all 10 measures in the survey, with improvements observed in each area. Respondents have expressed early signs of speculative bubbles, particularly in dealmaking activity and AI investments. The biopharma sector has never felt so vibrant and carbonated.
The BPSI is a global benchmark produced by Endpoints Signal, which surveys biopharma experts every quarter on five key areas: business conditions, company finances, funding climate, regulation, and hiring. In this edition, the survey captured the views of 569 verified industry insiders, with more than a quarter being C-suite executives. The survey was conducted from Aug. 13 to Sept. 15.
The most notable improvement came from current business conditions, which jumped to 103 from 87 in the previous quarter, indicating a high level of satisfaction with the present state of the industry. The factor that increased the most was current business conditions, with a sentiment score of 147, the highest ever recorded. However, the policy environment remained negative, with respondents calling for more stability and science-first policy-making.
The biggest surprise is the improvement in current conditions compared to future expectations. While expectations for the year ahead increased to 106 from 102, the gap between current conditions and future expectations has narrowed to less than 3 points. This means that the brighter future predictions are largely becoming a reality, presenting a new challenge for the industry: can biopharma's gains continue, or will high interest rates and an improving but still unstable regulatory environment put an end to the optimism?
Written by urgent.news from Endpoints News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
